Abiraterone plus Prednisone in Metastatic, Castration-Sensitive Prostate Cancer

20172,166 citationsJournal Articlebronze Open Access

Authors

Karim Fizazi · Université Paris-Sud

NamPhuong Tran · Université Paris-Sud

Luis Fein · Université Paris-Sud

Nobuaki Matsubara · Université Paris-Sud

A. Rodrı́guez-Antolı́n · Université Paris-Sud

B. Yа. Alekseev · Université Paris-Sud

Mustafa Özgüroğlu ·

Abstract

The addition of abiraterone acetate and prednisone to androgen-deprivation therapy significantly increased overall survival and radiographic progression-free survival in men with newly diagnosed, metastatic, castration-sensitive prostate cancer. (Funded by Janssen Research and Development; LATITUDE ClinicalTrials.gov number, NCT01715285 .).

Topics & Keywords

Prostate Cancer Treatment and Research Prostate Cancer Diagnosis and Treatment Hormonal and reproductive studies

Publication Details

Published in: New England Journal of Medicine

Volume 377, Issue 4, pp. 352-360

DOI: 10.1056/nejmoa1704174

Field-Weighted Citation Impact: 178.51

Command Palette

Abiraterone plus Prednisone in Metastatic, Castration-Sensitive Prostate Cancer

Authors

Abstract

Topics & Keywords

Publication Details